Tag

Tejash Maheshchandra Hathi

1 article

Aptus Pharma H1 PAT Rises to ₹5.07 Crore

Aptus Pharma approved unaudited H1 FY27 results with revenue of ₹48.92 crore and PAT of ₹5.07 crore, showing significant YoY growth. The company completed a 3:2 bonus share issue in May 2026, increasi